Physician profile
John E Hueter, JR.
NPI 1609876515
$3,429.15
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,806 · 2020: $1,083 · 2021: $502 · 2022: $38.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $523.13 | 2019-2020 | |
| Amgen INC. | $504.20 | 2019-2022 | |
| Allergan, INC. | $300.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $257.15 | 2019 | |
| Sunovion Pharmaceuticals INC. | $252.66 | 2019-2020 | |
| Abbvie INC. | $248.24 | 2021-2022 | |
| Genzyme Corporation | $183.97 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $174.40 | 2019-2020 | |
| Biogen, INC. | $168.21 | 2019-2020 | |
| Emd Serono, INC. | $157.51 | 2019-2020 | |
| Acorda Therapeutics, INC | $146.43 | 2019 | |
| Ucb, INC. | $89.94 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $81.06 | 2019-2020 | |
| Biofrontera INC. | $58.41 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $39.23 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.98 | 2019 | |
| Csl Behring | $28.86 | 2020 | |
| Grifols USA, LLC | $23.57 | 2019 | |
| Adamas Pharmaceuticals, INC. | $23.52 | 2019 | |
| Janssen Biotech, INC. | $19.76 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.88 | 2021 | |
| Ge Healthcare | $17.28 | 2020 | |
| Assertio Therapeutics, INC. | $16.41 | 2019 | |
| Osiris Therapeutics INC. | $16.02 | 2019 | |
| Mdd US Operations, LLC | $16.00 | 2019 | |
| Neurocrine Biosciences, INC. | $14.95 | 2020 | |
| Boston Scientific Corporation | $12.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hueter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.